Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

ASTRAZENECA

(AZN)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
11/07/2019 11/08/2019 11/11/2019 11/12/2019 11/13/2019 Date
7287(c) 7277(c) 7248(c) 7275(c) 7380 Last
1 446 480 1 212 375 1 195 401 1 115 608 300 159 Volume
-0.68% -0.14% -0.40% +0.37% +1.44% Change
More quotes
Financials (USD)
Sales 2019 24 436 M
EBIT 2019 6 580 M
Net income 2019 2 201 M
Debt 2019 11 604 M
Yield 2019 2,98%
Sales 2020 26 899 M
EBIT 2020 7 464 M
Net income 2020 3 404 M
Debt 2020 12 002 M
Yield 2020 3,00%
P/E ratio 2019 56,2x
P/E ratio 2020 37,7x
EV / Sales2019 5,54x
EV / Sales2020 5,05x
Capitalization 124 B
More Financials
Company
AstraZeneca is one of the world's leading pharmaceutical groups. Net sales break down by treatment area as follows: - cardiovascular, renal and metabolic diseases (31.9%); - oncology (28.6%); - respiratory diseases (23.3%); - other (16.2%): inflammatory and autoimmune diseases, neurological... 
Sector
Pharmaceuticals
Calendar
11/19Roadshow - Day 1
More about the company
Surperformance© ratings of AstraZeneca
Trading Rating : Investor Rating :
More Ratings
Latest news on ASTRAZENECA
11/11ROXADUSTAT POOLED ANALYSES : no increased CV risk
PU
11/08FibroGen, AstraZeneca Up After Roxadustat Data
DJ
11/08ASTRAZENECA : Roxadustat Phase III programme pooled analyses showed positive eff..
PU
11/08ASTRAZENECA : Roxadustat Phase III Program Pooled Analyses Showed Positive Effic..
BU
11/08ASTRAZENECA : New Data From the Phase III DAPA-HF Trial Showed FARXIGA Reduced t..
BU
11/08AstraZeneca Finds Increased Hemoglobinin in Roxadustat Phase 3 Trial
DJ
11/08ASTRAZENECA : Roxadustat significantly increased haemoglobin
PU
11/07ASTRAZENECA : Roxadustat significantly increased haemoglobin levels for chronic ..
PU
11/07ASTRAZENECA : Roxadustat Significantly Increased Hemoglobin Levels for Chronic K..
BU
11/06ASTRAZENECA : CALQUENCE® Data To Show Improved Progression-Free Survival In Phas..
BU
11/06ASTRAZENECA : Calquence data to show improved progression-free survival in Phase..
PU
11/06GLOBAL MARKETS LIVE : Xerox, T-Mobile, Sprint, IBM…
11/06ASTRAZENECA : Calquence data to show improved progression-free
PU
11/06NEWS HIGHLIGHTS : Top Company News of the Day
DJ
11/06NEWS HIGHLIGHTS : Top Company News of the Day
DJ
More news
News in other languages on ASTRAZENECA
11/12ASTRAZENECA : lance une étude pour le cancer de l'ovaire
11/12ASTRAZENECA : résultats positifs pour l'anifrolumab
11/11INNATE PHARMA : Citi débute sa couverture à l'Achat
11/08ASTRAZENECA : des données positives sur le Roxadustat
11/06ASTRAZENECA : un fonds d'investissement chinois dans la santé
More news
Analyst Recommendations on ASTRAZENECA
More recommendations
Sector news : Pharmaceuticals - NEC
02:48aCREDIT MARKETS : AbbVie's $30 Billion Sale of Debt Draws Strong Demand -- WSJ
DJ
11/12ABBVIE : Sells $30 Billion of Bonds -- 2nd Update
DJ
11/12AbbVie Prepares Large Bond Sale -- Update
DJ
11/12ABBVIE : Prepares Large Bond Sale to Fund Allergan Purchase
DJ
11/12MYLAN N : and Pfizer Say Combined -Upjohn to Be Called Viatris
DJ
More sector news : Pharmaceuticals - NEC
Chart ASTRAZENECA
Duration : Period :
AstraZeneca Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 100,46  $
Last Close Price 94,33  $
Spread / Highest target 43,4%
Spread / Average Target 6,50%
Spread / Lowest Target -24,9%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Marcus Wallenberg Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA23.87%123 868
JOHNSON & JOHNSON2.27%344 670
ROCHE HOLDING AG22.47%254 722
MERCK AND COMPANY10.09%211 953
PFIZER-15.30%208 023
NOVARTIS19.53%198 320